Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P890057/S029

MODEL 3100 FREQUENCY OSCILLATORY VENTILATOR

ZOLL MEDICAL CORPORATION · Decision date Jul 23, 2025

FDA DECISIONP890057/S029

What did the FDA approve?

FDA records P890057/S029 as a supplement to PMA P890057, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 23, 2025.

FDA approval order statement

for a change in the raw material base resin for the 772722-102 pressure sense line Flex, circuit 71.0 LG, used in the 3100 Series Ventilators Patient Circuit connectors.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Anesthesiology
Decision date
Jul 23, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P890057/S029
Regulatory pathway
PMA supplement
Product code
LSZ
Decision code
APPR
Decision date
Jul 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: VENTILATOR, HIGH FREQUENCY.

Product code
LSZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P890057/S029 received

    Application receipt date recorded by FDA.

  2. P890057/S029 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P890057. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LSZ

Product / regulatory recordCompanyPathwayDecision dateSource
Bunnell, Inc.PMA supplementSep 28, 2026FDA
Bunnell, Inc.PMA supplementMay 7, 2026FDA
Bunnell, Inc.PMA supplementJul 25, 2025FDA
Bunnell, Inc.PMA approvalJun 30, 1988FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ZOLL MEDICAL CORPORATION

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
269 Mill Rd., Chelsmford, MA, 01824

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records